Myelodysplastic Syndromes: all 2,165 studies
Page 13 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.
- IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCTTerminatedNCT03696537Phase 1
- Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid MalignanciesActive, not recruitingNCT03682029Not applicable
- Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic SyndromeCompletedNCT03672539Phase 2
- Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT03659084
- HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell TransplantationStatus unknownNCT03655145Phase 3
- Impact of 2 Transfusion Strategies on Quality of Life of Multitransfused Patients With Low-risk Myelodysplastic SyndromeTerminatedNCT03643042Not applicable
- Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell TransplantActive, not recruitingNCT03622788Phase 1/2
- Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPNActive, not recruitingNCT03613532Phase 1
- EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2WithdrawnNCT03612739Phase 1
- Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationWithdrawnNCT03602898Phase 2
- Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT03600155Phase 1
- Biological Predictive Factors of Response to ESA in Low Risk MDS PatientsCompletedNCT03598582Phase 4
- COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeActive, not recruitingNCT03595787Not applicable
- Efficiency of Antibacterial Prophylaxis in Azacitidine Treated PatientsCompletedNCT03594149Phase 3
- Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic TransplantTerminatedNCT03588936Phase 1
- Severe Immune Cytopenia Registry Www.Sic-reg.OrgCompletedNCT03576742
- A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDSCompletedNCT03573310Phase 1
- CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic SyndromeActive, not recruitingNCT03572764Phase 1
- A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type MalignanciesActive, not recruitingNCT03560882Phase 1
- Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic SyndromesCompletedNCT03558386
- A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351CompletedNCT03555955Phase 1
- A Post-Marketing Observational Study of VYXEOS™CompletedNCT03526926
- Ascorbic Acid Levels in MDS, AML, and CMML PatientsCompletedNCT03526666
- EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute LeukemiaTerminatedNCT03519984Phase 1
- A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic SyndromesCompletedNCT03516591Phase 1
- IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic SyndromeActive, not recruitingNCT03503409Phase 2
- Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDSCompletedNCT03502668Phase 1/2
- Study of SyB C-1101 in Patients With Myelodysplastic SyndromeCompletedNCT03495167Phase 1
- Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic SyndromeSuspendedNCT03494569Phase 1
- Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486CompletedNCT03493646Phase 2
- A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic SyndromeWithdrawnNCT03486353Phase 2
- Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood TransplantationCompletedNCT03483324Phase 1
- Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS)CompletedNCT03469661
- Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDSCompletedNCT03459859Phase 1
- SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell TransplantationStatus unknownNCT03454984Phase 2
- iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic SyndromesWithdrawnNCT03446638Not applicable
- Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell TransplantWithdrawnNCT03438344Phase 2
- Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With PosaconazoleCompletedNCT03434704Phase 2
- RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCTStatus unknownNCT03412266Phase 2
- Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute LeukemiaStatus unknownNCT03408210Not applicable
- Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic SyndromeTerminatedNCT03404193Phase 2
- TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic AcidCompletedNCT03397173Phase 2
- CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic SyndromeCompletedNCT03393611Phase 1
- Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA AgentsCompletedNCT03387475Phase 2
- Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)WithdrawnNCT03377725Phase 3
- QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AMLWithdrawnNCT03365661Phase 2
- Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic SyndromesCompletedNCT03363399
- Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic SyndromeCompletedNCT03359460Phase 1
- DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast ExcessStatus unknownNCT03356080Phase 2
- Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2CompletedNCT03338348Phase 2
- Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic SyndromeCompletedNCT03337451Phase 1/2
- Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation StudyStatus unknownNCT03335943Phase 4
- A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive TherapyActive, not recruitingNCT03310918Not applicable
- Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)CompletedNCT03303066Phase 2/3
- Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell TransplantActive, not recruitingNCT03301168Phase 1/2
- Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesCompletedNCT03263637Phase 1
- Nivolumab With Chemotherapy in Refractory MDSTerminatedNCT03259516Phase 1/2
- Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN)Status unknownNCT03258359Phase 1
- Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic SyndromesStatus unknownNCT03235973Phase 1
- Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy DonorsTerminatedNCT03233074
- HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid HemopathiesCompletedNCT03232268Phase 1
- A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDSActive, not recruitingNCT03223961Phase 3
- High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE)Status unknownNCT03217903Not applicable
- Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDSCompletedNCT03187288Phase 1
- Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)SuspendedNCT03184935Phase 1/2
- A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCTCompletedNCT03176849Phase 4
- Clinical and Genomic Registry of MDS in AsiaStatus unknownNCT03169296
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT03164057Phase 2
- iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AMLWithdrawnNCT03138395
- Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic SyndromesActive, not recruitingNCT03121014Phase 2
- Development of an in Vitro Hematopoietic Culture System and Application to Myelodysplastic Syndromes.CompletedNCT03107273
- Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)Status unknownNCT03091933Phase 1/2
- Haploidentical Stem Cell Transplantation Using Post-Transplant CyclophosphamideTerminatedNCT03088709Phase 2
- Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot StudyWithdrawnNCT03086252Not applicable
- Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid LeukemiaStatus unknownNCT03083054Phase 1/2
- Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDSCompletedNCT03074006Phase 1
- Collection of Samples From Patients With MDSStatus unknownNCT03072498
- Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDSCompletedNCT03066648Phase 1
- Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMTWithdrawnNCT03066466Phase 3
- A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDSWithdrawnNCT03059615Phase 2
- Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS)WithdrawnNCT03057990Phase 1
- Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion DependentStatus unknownNCT03045510Phase 2
- A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)CompletedNCT03030612Phase 1/2
- Clinical Sequencing of Cancer and Tissue Repository: OncoGenomicsWithdrawnNCT03027401
- A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer IndicationsStatus unknownNCT03018405Phase 1/2
- Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)TerminatedNCT03016130Phase 3
- Haploidentical BMT With Post-Transplant Cyclophosphamide and BendamustineCompletedNCT02996773Phase 1
- CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaCompletedNCT02995655Phase 1
- Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPYTerminatedNCT02992860Phase 2
- Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic SyndromeCompletedNCT02979366Phase 1
- Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDSCompletedNCT02969980Phase 2
- A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)CompletedNCT02966782Phase 1
- Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
- Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant RecoveryCompletedNCT02955043Not applicable
- A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)CompletedNCT02942290Phase 1
- CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCTCompletedNCT02942173Phase 2/3
- Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or RelapsedActive, not recruitingNCT02935361Phase 1/2
- Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5qTerminatedNCT02928419Phase 2
- Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDSWithdrawnNCT02923986Phase 1/2
- A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid TreatmentCompletedNCT02921815